Moderna Pipeline For Any Vaccine Beyond Covid Is 'Underappreciated,' Analyst Says
Portfolio Pulse from Priya Nigam
Moderna's stock rose after submitting an updated vaccine application to the FDA. UBS analyst Eliana Merle upgraded Moderna's rating from Neutral to Buy, citing underappreciated potential for mRNA vaccines in diseases beyond Covid. The price target was reduced from $221 to $191.

June 26, 2023 | 2:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS analyst Eliana Merle upgraded Moderna's rating to Buy, citing underappreciated potential for mRNA vaccines in diseases beyond Covid. The price target was reduced from $221 to $191.
The upgrade in rating from UBS analyst Eliana Merle indicates a positive outlook for Moderna's stock, as she believes the potential for mRNA vaccines in diseases beyond Covid is underappreciated. This could lead to increased investor interest and a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100